Effects of flumazenil on recovery sleep and hormonal secretion after sleep deprivation in male controls.
The effects of flumazenil, a benzodiazepine antagonist, on the sleep electroencephalogram (EEG) and neuroendocrine secretion in early morning recovery sleep (0500-0800 hours) following sleep deprivation (SD; 2300-0500 hours) were studied in seven healthy men. SD induced an increase in slow wave sleep (SWS), a decrease in sleep onset latency (SOL), an enhancement of EEG delta and theta power in non-rapid-eye-movement sleep, an increase in plasma human growth hormone (GH) concentration, and a decrease in plasma cortisol levels in recovery sleep (0500-0800 hours). Plasma GH, but neither plasma cortisol nor adrenocorticotrophic hormone (ACTH) concentration was attenuated during SD as compared to sleep (2300-0445 hours). The administration of flumazenil (3 x 1 mg intravenously) during recovery sleep resulted in an inhibition in SWS, an increase in stage 2 sleep, a selective reduction in delta and theta power, and a tendency to prolongation of SOL. Plasma GH concentration was decreased but plasma cortisol and ACTH remained unaffected. Since the SD-induced changes in sleep EEG and plasma GH secretion were antagonized by flumazenil, it is suggested that electrophysiological and hormonal effects of SD are mediated at least in part through GABAergic mechanisms.
Depression Research Unit, Psychiatric University Hospital, Basel, Switzerland.
E
E
Seifritz
U
U
Hemmeter
L
L
Trachsel
C J
CJ
Lauer
M
M
Hatzinger
H M
HM
Emrich
F
F
Holsboer
E
E
Holsboer-Trachsler
D000324:Adrenocorticotropic Hormone / Q000097:blood*; D000328:Adult; D004569:Electroencephalography; D005442:Flumazenil / Q000494:pharmacology*; D013006:Growth Hormone / Q000097:blood*; D006801:Humans; D006854:Hydrocortisone / Q000097:blood*; D008297:Male; D012890:Sleep / Q000187:drug effects*; D012892:Sleep Deprivation / Q000502:physiology*; D013997:Time Factors
D005442:Flumazenil; D000324:Adrenocorticotropic Hormone; D013006:Growth Hormone; D006854:Hydrocortisone